Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition

A subset of lung adenocarcinomas is driven by the EML4‐ALK translocation. Even though ALK inhibitors in the clinic lead to excellent initial responses, acquired resistance to these inhibitors due to on‐target mutations or parallel pathway alterations is a major clinical challenge. Exploring these me...

Descripción completa

Detalles Bibliográficos
Autores principales: Paliouras, Athanasios R, Buzzetti, Marta, Shi, Lei, Donaldson, Ian J, Magee, Peter, Sahoo, Sudhakar, Leong, Hui‐Sun, Fassan, Matteo, Carter, Matthew, Di Leva, Gianpiero, Krebs, Matthew G, Blackhall, Fiona, Lovly, Christine M, Garofalo, Michela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338803/
https://www.ncbi.nlm.nih.gov/pubmed/32558295
http://dx.doi.org/10.15252/emmm.201911099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338803/
https://www.ncbi.nlm.nih.gov/pubmed/32558295
http://dx.doi.org/10.15252/emmm.201911099

Ejemplares similares